Compare NPK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | DRUG |
|---|---|---|
| Founded | 1905 | 2019 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.2M | 856.4M |
| IPO Year | N/A | N/A |
| Metric | NPK | DRUG |
|---|---|---|
| Price | $126.47 | $83.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $106.75 |
| AVG Volume (30 Days) | 76.4K | ★ 120.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.63 | $23.18 |
| 52 Week High | $137.78 | $123.75 |
| Indicator | NPK | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 54.94 |
| Support Level | $119.22 | $74.21 |
| Resistance Level | $137.78 | $78.34 |
| Average True Range (ATR) | 4.58 | 5.59 |
| MACD | -1.33 | 0.22 |
| Stochastic Oscillator | 35.76 | 88.54 |
National Presto Industries Inc has an eclectic product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments namely Defense, Housewares/Small Appliance, and Safety. The defense segment which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases; performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances; the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.